National and Kapodistrian University of Athens
Κλινική και εργαστηριακή αξιολόγηση του ανοσοποιητικού συστήματος σε ασθενείς με καρκίνο του πνεύμονα που λαμβάνουν θεραπεία με αναστολείς των σημείων ελέγχου (checkpoint inhibitors)
Abstract
dc:descriptionBackground: In-treatment monitoring of immunological and other peripheral blood parameters may reveal complementary biomarkers for immunotherapy in lung cancer. Objectives: To characterize the kinetics of peripheral blood immune parameters and investigate their association with clinical outcomes during immunotherapy. Methods: Patients with metastatic non-small cell lung cancer (NSCLC) receiving first-line pembrolizumab monotherapy were prospectively enrolled. Plasma samples were collected at predefined timepoints during the first year of treatment. Analyses included complete blood counts, biochemical parameters, cytokines, autoantibodies, soluble PD-L1 (sPD-L1), and pembrolizumab trough concentrations (Cmin). Clinical outcomes were assessed over a two-year follow-up period. Results: A total of 31 patients were enrolled over a two-year period. CRP, IL-6, IL-17α, and IL-8 levels decreased significantly during the first year of treatment (p < 0.01). White blood cells, neutrophils, CRP, and MIP-3α/CCL20 exhibited significant changes during the first three months of therapy (p < 0.01). Early kinetic analysis demonstrated a significant decrease in patients with high baseline LDH levels (p < 0.01), while significant increases in CXCL11 (p < 0.05), GM-CSF (p < 0.01), IL-4 (p < 0.05), and sPD-L1 (p < 0.05) were observed among patients with low baseline values. Pre-treatment autoantibody seropositivity was detected in 38.7% of patients, with limited dynamic changes during treatment (seroreversion 3.2%, emergence of new autoantibodies 30.8%, and seroconversion 9.7%). Pembrolizumab Cmin increased significantly during the first three months of treatment (p < 0.0001) and subsequently remained stable. Dynamic changes in immune parameters were not associated with clinical outcomes. In contrast, higher baseline levels of CRP, complement protein C4, and IL-6 were associated with poorer clinical outcomes. C4 emerged as an independent predictor of clinical benefit, while the integration of CRP, C4, and IL-6 into composite multiparametric scores improved prognostic performance. Conclusions: Monitoring selected peripheral blood biomarkers associated with systemic inflammation and an immune-resistant phenotype may provide clinically relevant prognostic information in patients receiving immunotherapy. The integration of these biomarkers into multiparametric models may improve the prediction of treatment outcomes and contribute to patient stratification. These findings require validation in larger prospective cohorts.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2026
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Trontzas, Ioannis
- Τρόντζας, Ιωάννης
Subjects
dc:subject × 18- Καρκίνος πνεύμονα
- Ανοσοθεραπεία
- Ανοσοποιητικό σύστημα
- Περιφερικοί ανοσολογικοί δείκτες
- Βιοδείκτες
- Αναστολείς σημείων ελέγχου
- Lung cancer
- Immunotherapy
- Immune system
- Peripheral immune markers
- Biomarkers
- Immune checkpoint inhibitors
- Κλινική Ιατρική
- Ιατρική και Επιστήμες Υγείας
- Ογκολογία
- Clinical Medicine
- Medical and Health Sciences
- Oncology
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/62139